The Managed Ventricular pacing versus VVI 40 Pacing (MVP) Trial: clinical background, rationale, design, and implementation.

about

The Managed Ventricular pacing versus VVI 40 Pacing (MVP) Trial: clinical background, rationale, design, and implementation.

Item

http://www.wikidata.org/entity/Q51109683

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年学术文章

@wuu

2006年学术文章

@zh

2006年学术文章

@zh-cn

2006年学术文章

@zh-hans

2006年学术文章

@zh-my

2006年学术文章

@zh-sg

2006年學術文章

@yue

2006年學術文章

@zh-hant

name

The Managed Ventricular pacing ...... e, design, and implementation.

@en

The Managed Ventricular pacing ...... e, design, and implementation.

@nl

type

Item

label

The Managed Ventricular pacing ...... e, design, and implementation.

@en

The Managed Ventricular pacing ...... e, design, and implementation.

@nl

prefLabel

The Managed Ventricular pacing ...... e, design, and implementation.

@en

The Managed Ventricular pacing ...... e, design, and implementation.

@nl

P1476

The Managed Ventricular pacing ...... e, design, and implementation.

@en

P2093

David Whellan

http://www.w3.org/2001/XMLSchema#string

Elaine Hogan Miller

http://www.w3.org/2001/XMLSchema#string

Lou Sherfesee

http://www.w3.org/2001/XMLSchema#string

Michael O Sweeney

http://www.w3.org/2001/XMLSchema#string

Todd Sheldon

http://www.w3.org/2001/XMLSchema#string

P2860

ACC/AHA/NASPE 2002 guideline update for implantation of cardiac pacemakers and antiarrhythmia devices: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/NASPE Commit

Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction

Canadian implantable defibrillator study (CIDS) : a randomized trial of the implantable cardioverter defibrillator against amiodarone.

A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias.

Dual-chamber pacing or ventricular backup pacing in patients with an implantable defibrillator: the Dual Chamber and VVI Implantable Defibrillator (DAVID) Trial.

Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.

Sample size estimates for atrial fibrillation endpoints.

Cost advantage of dual-chamber versus single-chamber cardioverter-defibrillator implantation.

A new paradigm for physiologic ventricular pacing.

Good enough: a primer on the analysis and interpretation of noninferiority trials.

P304

1295-1298

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1540-8167.2006.00656.X

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Kenneth A Ellenbogen

P577

2006-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17081208

http://www.w3.org/2001/XMLSchema#string